ESMO 2017 - Postconference Report

23 October 2017

This report is a collection of BPI’s articles related to our attendance at the 2017 ESMO (European Society for Medical Oncology) conference. It includes coverage based on our discussions with key opinion leaders about how the most important information coming out of the meeting will impact the drug development sector. It also includes trends and intel that the investigative journalist team gathered during the conference.

A sampling of headlines:
• Array’s BEACON for CRC needs to find edge over comparable triplets to secure uptake success despite huge unmet need – experts
• Blueprint plans to use BLU-554 once-daily 600mg in future Phase II HCC trial after twice-daily version shows Phase I toxicity – sources
• BMS to submit FDA filing for Opdivo & Opdivo/Yervoy for second/third-line mesothelioma by YE17 based on investigator-sponsored study – source
• BMS’ analysis of CheckMate153 in NSCLC unlikely to change oncologists practice with PD-1/PD-L1 inhibitors- experts
• Exelixis’ updated Cabometyx data spurs expert backing for use in heavy-diseaseburden 1L RCC patients, but most declare BMS’ Opdivo/Yervoy new SOC
• Incyte’s Phase III epacadostat trial for melanoma draws unclear OS forecast, but achievable PFS and positive safety profile provides upside – experts
• MacroGenics’ flotetuzumab AML/MDS data shows appealing activity but interim data population too small to ascertain CR significance – experts